Continuous Versus Cyclic Oral Contraceptives for Endometriosis

Continuous Versus Cyclic Use of Oral Contraceptives Following Surgery for Symptomatic Endometriosis

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02237131

Enrollment

Registered

2014-09-11

Start date

2014-04-30

Completion date

2015-12-31

Last updated

2014-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysmenorrhea, Dyspareunia, Endometrioma, Pelvic Pain

Keywords

Endometriosis, Oral contraceptives, Laparoscopy

Brief summary

To evaluate the efficacy of oral contraceptives in a continuous fashion versus the usual cyclic fashion in the recurrence of endometriosis related symptoms and endometriomas following fertility-sparing surgery.

Detailed description

Oral contraceptives containing 0.03 mg ethinyl estradiol and 3mg drospirenone will be administered. One tablet a day for 21 days followed by 7 days pill free (cyclic fashion) or one tablet a day in a continuous fashion.

Interventions

DRUGOral contraceptives cyclic

tables containing Ethinyl estradiol 0.03mg and drospirenone 3mg will be administered in a cyclic fashion 21 days on 7 days off pill for 6 cycles.

DRUGOral contraceptives continuous

Patients will be treated with oral contraceptives containing 0.03mg ethinyl estradiol and 3 mg drospirenone per day in a continuous fashion.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

Women of reproductive age with Symptomatic endometriosis following fertility sparing surgery

Exclusion criteria

Contraindications of use of oral contraceptives

Design outcomes

Primary

Measure	Time frame	Description
Pelvic pain	6 months	In each visit patients will complete a detailed 25-item self-administered questionnaire (www.endometriosisfoundation.org/WERF-WHSS-Questionnaire-English.pdf) related to the presence of pelvic pain (scoring of pelvic pain)

Secondary

Measure	Time frame	Description
recurrence rate for endometrioma	6 months	Physical and transvaginal sonographic examination

Other

Measure	Time frame	Description
dysmenorrhea	6 months	In each visit patients were asked to complete a detailed 25-item self-administered questionnaire (www.endometriosisfoundation.org/WERF-WHSS-Questionnaire-English.pdf) related to the presence of dysmenorrhea (scoring of dysmenorrhea)

Countries

Greece

Contacts

Primary ContactOlga B Triantafyllidou, M.D, Msc

triantafyllidouolga@yahoo.com+306944963506

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026